TABLE 4

Analysis of GMTs for Measles, Mumps, Rubella, and Varicella at 6 Weeks After Vaccination

ComparisonMeaslesMumpsRubellaVaricella
GMT, mIU/mL (A)GMT, mIU/mL (B)Estimated Fold Difference (90% CI)GMT, ELISA U/mL (A)GMT, ELISA U/mL (B)Estimated Fold Difference (90% CI)GMT, IU/mL (A)GMT, IU/mL (B)Estimated Fold Difference (90% CI)GMT, gpELISA U/mL (A)GMT, gpELISA U/mL (B)Estimated Fold Difference (90% CI)
ProQuad + placebo (group 1) (A) versus M-M-RII + placebo (group 2) (B)1971.82062.40.96 (0.88–1.04)206.4310.90.66 (0.59–0.74)212.1178.91.19 (1.07–1.31)NANANA
ProQuad + placebo (group 1) (A) versus M-M-RII + Varivax (group 3) (B)1971.82099.40.94 (0.86–1.02)206.4292.00.71 (0.63–0.79)212.1157.51.35 (1.21–1.50)317.0212.41.4 (1.26–1.76)
M-M-RII + Varivax (group 3) (A) versus M-M-RII + placebo (group 2) (B)2099.42062.41.02 (0.92–1.12)292.0310.90.94 (0.82–1.07)157.5178.90.88 (0.78–0.99)NANANA
  • GMTs, fold differences, and 90% CIs are based on a statistical analysis model adjusting for prevaccination titer, study center, and primary vaccination history status. NA indicates not available.